文献速递银屑病与炎症性皮肤病自身免疫性与大疱性皮肤病毛发、甲与色素性疾病

自身免疫性皮肤病与癌症抗肿瘤治疗后的生存结局

Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer.
PubMed 文献 · JAMA Dermatol · 2025-01-01

ASD组全因死亡IPTW调整HR为0.94(95%CI 0.92-0.96),癌症特异死亡SHR为0.94(95%CI 0.92-0.96),提示ASD与更好的癌症生存相关。

要点

  • 合并ASD的癌症患者全因死亡风险更低(IPTW调整HR 0.94,95%CI 0.92-0.96)。
  • 癌症特异死亡风险同样更低(SHR 0.94,95%CI 0.92-0.96)。
  • 斑秃和干燥综合征与较低死亡风险 consistently 相关。

核心结论

  • 合并自身免疫性皮肤病的癌症患者接受抗肿瘤治疗后生存结局显著优于无ASD者。

研究设计与样本

  • 采用IPTW和倾向性评分匹配控制混杂,Cox模型估计全因死亡HR,Fine-Gray模型估计癌症特异死亡SHR(非癌死亡为竞争事件)。

主要发现

  • ASD组全因死亡IPTW调整HR为0.94(95%CI 0.92-0.96),癌症特异死亡SHR为0.94(95%CI 0.92-0.96)。
  • 倾向性评分匹配分析结果一致。
  • ASD亚型中斑秃和干燥综合征与较低死亡风险 consistently 相关。

临床怎么用

  • 提示ASD可能与癌症预后存在免疫学关联,临床管理中可关注ASD状态对肿瘤治疗结局的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autoimmune skin diseases (ASDs) and cancer both involve immune system dysregulation, with ASDs characterized by heightened immune activity, and cancer associated with immune evasion; however, their impact on cancer prognosis remains unclear. OBJECTIVE: To investigate the association of ASDs with cancer prognosis and survival outcomes after antineoplastic treatment in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from Taiwan's Nationwide Cancer Registry and National Health Insurance Database to evaluate survival outcomes in patients with cancer who received antineoplastic treatment (ie, chemotherapy, targeted therapy, or immunotherapy) between January 1, 2019, and June 30, 2021. Data were analyzed from July 2023 to April 2025. EXPOSURES: ASDs, including alopecia areata, Sjögren syndrome, vitiligo, cutaneous lupus erythematosus, psoriasis, lichen planus, autoimmune bullous diseases, systemic sclerosis, morphea, hidradenitis, and dermatomyositis. MAIN OUTCOME AND MEASURES: All-cause mortality and cancer-specific mortality were assessed during the follow-up period. To account for potential confounding, both inverse probability of treatment weighting (IPTW) and propensity score matching strategies were applied. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) for all-cause mortality, while the Fine-Gray hazard model was used to estimate subdistribution HRs (SHRs) for cancer-specific mortality, with noncancer-related deaths considered as competing events. RESULTS: Of 197 895 patients included in the analysis, 26 008 were in the ASD group (mean [SD] age, 64.0 [13.3] years; 14 969 female [57.6%]) and 171 887 were in the non-ASD group (mean [SD] age, 62.8 [13.0] years; 80 525 female [46.9%]). Patients with ASDs had significantly better survival outcomes than those without ASDs, with an IPTW-adjusted HR of 0.94 (95% CI, 0.92-0.96) for all-cause mortality and an SHR of 0.94 (95% CI, 0.92-0.96) for cancer-specific mortality. These associations remained consistent in propensity score-matched analyses. Among ASD subtypes, alopecia areata and Sjögren syndrome were consistently associated with lower mortality risk. CONCLUSIONS AND RELEVANCE: This population-based cohort study found that patients with ASDs had significantly better cancer survival outcomes than those without ASDs. This finding suggests that there is a potential immunological association between ASDs and cancer prognoses, highlighting the need for further investigation into the underlying mechanisms and the implications for oncologic management.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. To SY, Lee CH, Chen YH, et al. Autoimmune Skin Diseases and Survival Outcomes After Antineoplastic Treatment in Patients With Cancer. JAMA Dermatol. 2025. PMID: 40601336. doi:10.1001/jamadermatol.2025.1949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。